Biogen Inc Evaluation Of Aducanumab Efficacy And Safety In Early Alzheimer's Disease Discussion at AD/PD Conference Call Transcript

Mar 13, 2021

Click here to view more BIIB transcripts

Mar 13, 2021 / 11:45AM GMT
Randall J. Bateman -

We're going to be discussing the amyloid beta targeting therapies in Alzheimer's disease session 2. I'm Randy Bateman. I'm a Professor of Neurology at Washington University and the Director of The Dominantly Inherited Alzheimer's Network and Trials Unit. Chad?

Chad Swanson -

Hi, everybody. I'm Chad Swanson in the Neurology Business Group at Eisai and Clinical Development, and I am the international project team leader for aducanumab or BAN24 (sic) [BAN2401].

Randall J. Bateman -

Great. And Mark?

Mark A. Mintun -

I'm Mark Mintun, and I head the Alzheimer's disease development area for Eli Lilly and Company.

Randall J. Bateman -

Great. And Samantha?

Samantha Budd Haeberlein - Biogen Inc. - VP of Clinical Development

Hi there. Good morning, good afternoon. I'm Samantha Budd. I work at Biogen, and I head up the Neurodegeneration Development group. Thank you.

Randall J. Bateman -

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.